{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:45:00Z","timestamp":1757313900338},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Joint special fund of Yunnan science and technology department - Kunming medical university","award":["2018FE001(-056)"],"award-info":[{"award-number":["2018FE001(-056)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12325-022-02315-x","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T21:02:50Z","timestamp":1665608570000},"page":"5514-5529","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of Trimetazidine in Patients with Chronic Heart Failure Stratified by the Expression of Soluble Suppression of Tumorigenicity-2 (sST2): A Prospective Cohort Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Zhu","family":"Min","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Xuelu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Qiuhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"2315_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ijcard.2019.05.063","volume":"293","author":"M Marzilli","year":"2019","unstructured":"Marzilli M, Vinereanu D, Lopaschuk G, et al. Trimetazidine in cardiovascular medicine. Int J Cardiol. 2019;293:39\u201344.","journal-title":"Int J Cardiol"},{"key":"2315_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/NHH.0000000000000777","volume":"37","author":"T Capriotti","year":"2019","unstructured":"Capriotti T, Micari M. chronic heart failure treatment with the left ventricular assist device. Home Healthc Now. 2019;37:190\u20137.","journal-title":"Home Healthc Now"},{"key":"2315_CR3","doi-asserted-by":"crossref","unstructured":"Cui X, Hu K, Ge J. Current status of heart failure in China. Cardiol Plus. 2017;2:13. http:\/\/www.cardiologyplus.org\/text.asp?2017\/2\/2\/13\/248468.","DOI":"10.4103\/2470-7511.248468"},{"key":"2315_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/cvr\/cvr038","volume":"90","author":"V Lionetti","year":"2011","unstructured":"Lionetti V, Stanley WC, Recchia FA. Modulating fatty acid oxidation in heart failure. Cardiovasc Res. 2011;90:202\u20139.","journal-title":"Cardiovasc Res"},{"key":"2315_CR5","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3389\/fphar.2020.569132","volume":"11","author":"H Shu","year":"2021","unstructured":"Shu H, Peng Y, Hang W, Zhou N, Wang DW. Trimetazidine in heart failure. Front Pharmacol. 2021;11:1753. https:\/\/doi.org\/10.3389\/fphar.2020.569132.","journal-title":"Front Pharmacol"},{"key":"2315_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2515\/therapie:2005061","volume":"60","author":"J-F Mart\u00ed Mass\u00f3","year":"2005","unstructured":"Mart\u00ed Mass\u00f3 J-F, Mart\u00ed I, Carrera N, Poza J-J, L\u00f3pez de Munain A. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie. 2005;60:419\u201322.","journal-title":"Therapie"},{"key":"2315_CR7","first-page":"220","volume":"52","author":"J Kwon","year":"2019","unstructured":"Kwon J, Yu YM, Kim S, Jeong KH, Lee E. Association between trimetazidine and parkinsonism: a population-based study. NED. 2019;52:220\u20136.","journal-title":"NED"},{"key":"2315_CR8","doi-asserted-by":"publisher","first-page":"10050","DOI":"10.1038\/s41598-020-66692-5","volume":"10","author":"D Pint\u00e9r","year":"2020","unstructured":"Pint\u00e9r D, Juh\u00e1sz A, Harmat M, Janszky J, Kov\u00e1cs N. The impact of trimetazidine on disease severity and quality of life in Parkinson\u2019s disease. Sci Rep. 2020;10:10050.","journal-title":"Sci Rep"},{"key":"2315_CR9","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2147\/NDT.S157441","volume":"14","author":"M Liu","year":"2018","unstructured":"Liu M, Wei W, Stone CR, Zhang L, Tian G, Ding JN. Beneficial effects of trimetazidine on expression of serotonin and serotonin transporter in rats with myocardial infarction and depression. Neuropsychiatr Dis Treat. 2018;14:787\u201397.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2315_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10517-017-3677-2","volume":"162","author":"LG Kolik","year":"2017","unstructured":"Kolik LG, Nadorova AV, Stolyaruk VN, Miroshkina IA, Tsorin IB, Kryzhanovskii SA. Anxiolytic properties of trimetazidine in experimental models of increased anxiety. Bull Exp Biol Med. 2017;162:643\u20136.","journal-title":"Bull Exp Biol Med"},{"key":"2315_CR11","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","volume":"74","author":"A Aimo","year":"2019","unstructured":"Aimo A, Januzzi JL, Bayes-Genis A, et al. Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week. J Am Coll Cardiol. 2019;74:2193\u2013203.","journal-title":"J Am Coll Cardiol"},{"key":"2315_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cca.2019.10.029","volume":"501","author":"M Lotierzo","year":"2020","unstructured":"Lotierzo M, Dupuy AM, Kalmanovich E, Roubille F, Cristol JP. sST2 as a value-added biomarker in heart failure. Clin Chim Acta. 2020;501:120\u201330.","journal-title":"Clin Chim Acta"},{"key":"2315_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/00015385.2019.1669847","volume":"75","author":"M Barutaut","year":"2020","unstructured":"Barutaut M, Fournier P, Peacock WF, et al. sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure. Acta Cardiol. 2020;75:739\u201347.","journal-title":"Acta Cardiol"},{"key":"2315_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cca.2015.10.034","volume":"452","author":"AR van der Velde","year":"2016","unstructured":"van der Velde AR, Lexis CPH, Meijers WC, et al. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin Chim Acta. 2016;452:50\u20137.","journal-title":"Clin Chim Acta"},{"key":"2315_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jchf.2016.09.010","volume":"5","author":"A Aimo","year":"2017","unstructured":"Aimo A, Vergaro G, Passino C, et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure. JACC Heart Fail. 2017;5:280\u20136.","journal-title":"JACC Heart Fail"},{"key":"2315_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.685904","volume":"8","author":"C Yang","year":"2021","unstructured":"Yang C, Fan Z, Wu J, et al. The diagnostic value of soluble ST2 in heart failure: a meta-analysis. Front Cardiovasc Med. 2021;8: 685904.","journal-title":"Front Cardiovasc Med"},{"key":"2315_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1620\/tjem.250.233","volume":"250","author":"VT Mitic","year":"2020","unstructured":"Mitic VT, Stojanovic DR, Deljanin Ilic MZ, et al. Cardiac remodeling biomarkers as potential circulating markers of left ventricular hypertrophy in heart failure with preserved ejection fraction. Tohoku J Exp Med. 2020;250:233\u201342.","journal-title":"Tohoku J Exp Med"},{"key":"2315_CR18","unstructured":"FDA. Substantial equivalence determination decision summary assay only template. http:\/\/www.accessdata.fda.gov\/cdrh_docs\/reviews\/k111452.pdf.\nAccessed 5 May 2021."},{"key":"2315_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2217\/fca.09.26","volume":"5","author":"P Di Napoli","year":"2009","unstructured":"Di Napoli P, Taccardi AA. Trimetazidine: the future of cardiac function? Future Cardiol. 2009;5:421\u20134. https:\/\/doi.org\/10.2217\/fca.09.26.","journal-title":"Future Cardiol"},{"key":"2315_CR20","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jacc.2006.03.060","volume":"48","author":"G Fragasso","year":"2006","unstructured":"Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006;48:992\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"2315_CR21","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1161\/CIRCULATIONAHA.108.778019","volume":"118","author":"H Tuunanen","year":"2008","unstructured":"Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118:1250\u20138.","journal-title":"Circulation"},{"key":"2315_CR22","first-page":"75","volume":"32","author":"J Zhang","year":"2016","unstructured":"Zhang J, He S, Wang X, Wang D. Effect of trimetazidine on heart rate variability in elderly patients with acute coronary syndrome. Pak J Med Sci. 2016;32:75\u20138.","journal-title":"Pak J Med Sci"},{"key":"2315_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1365-2125.1994.tb04276.x","volume":"37","author":"JM Detry","year":"1994","unstructured":"Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol. 1994;37:279\u201388.","journal-title":"Br J Clin Pharmacol"},{"key":"2315_CR24","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/hrt.2010.208751","volume":"97","author":"D Gao","year":"2011","unstructured":"Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97:278\u201386.","journal-title":"Heart"},{"key":"2315_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1590\/S0066-782X2009000800014","volume":"93","author":"Y Gunes","year":"2009","unstructured":"Gunes Y, Guntekin U, Tuncer M, Sahin M. The effects of trimetazidine on heart rate variability in patients with heart failure. Arq Bras Cardiol. 2009;93:154\u20138.","journal-title":"Arq Bras Cardiol"},{"key":"2315_CR26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.lfs.2012.03.015","volume":"92","author":"P Zhao","year":"2013","unstructured":"Zhao P, Zhang J, Yin X-G, et al. The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy. Life Sci. 2013;92:633\u20138.","journal-title":"Life Sci"},{"key":"2315_CR27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ihj.2016.04.023","volume":"68","author":"S Jatain","year":"2016","unstructured":"Jatain S, Kapoor A, Sinha A, et al. Metabolic manipulation in dilated cardiomyopathy: assessing the role of trimetazidine. Indian Heart J. 2016;68:803\u20138.","journal-title":"Indian Heart J"},{"key":"2315_CR28","first-page":"200","volume":"18","author":"\u0130 G\u00fcl","year":"2017","unstructured":"G\u00fcl \u0130, Y\u00fccel O, Zarars\u0131z A, et al. Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure. Anatol J Cardiol. 2017;18:200\u20135.","journal-title":"Anatol J Cardiol"},{"key":"2315_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12325-009-0024-7","volume":"26","author":"G Marazzi","year":"2009","unstructured":"Marazzi G, Gebara O, Vitale C, et al. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. Adv Ther. 2009;26:455\u201361.","journal-title":"Adv Ther"},{"key":"2315_CR30","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.ehj.2004.06.034","volume":"25","author":"C Vitale","year":"2004","unstructured":"Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004;25:1814\u201321.","journal-title":"Eur Heart J"},{"key":"2315_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fneur.2020.00044","volume":"11","author":"AMB Dy","year":"2020","unstructured":"Dy AMB, Limjoco LLG, Jamora RDG. Trimetazidine-induced parkinsonism: a systematic review. Front Neurol. 2020;11:44.","journal-title":"Front Neurol"},{"key":"2315_CR32","doi-asserted-by":"publisher","unstructured":"Bohdan M, Stopczy\u0144ska I, Wi\u015bniewski P, Mory\u015b J, Niedoszytko P, Grucha\u0142a M. Effects of trimetazidine in patients with severe chronic heart failure with reduced left ventricular ejection fraction: a prospective, randomized, open-label, cross-over study. Cardiol J. 2022;29(4):627\u201336. https:\/\/doi.org\/10.5603\/CJ.a2020.0165.","DOI":"10.5603\/CJ.a2020.0165"},{"key":"2315_CR33","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s00059-015-4392-2","volume":"41","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Peng L, Luo Y, et al. Trimetazidine improves exercise tolerance in patients with ischemic heart disease: a meta-analysis. Herz. 2016;41:514\u201322. https:\/\/doi.org\/10.1007\/s00059-015-4392-2.","journal-title":"Herz."},{"key":"2315_CR34","doi-asserted-by":"publisher","first-page":"C128","DOI":"10.1016\/j.jacc.2017.07.459","volume":"70","author":"L Yuanhong","year":"2017","unstructured":"Yuanhong L, Chunying L, Hongwen F, Lie L, Dongli C, Silin C. GW28-e1225 the cardioprotective effects of trimetazidine in dilated cardiomyopathy patients with left bundle branch block. J Am Coll Cardiol. 2017;70:C128\u2013C128.","journal-title":"J Am Coll Cardiol"},{"key":"2315_CR35","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004382","author":"OF AbouEzzeddine","year":"2017","unstructured":"AbouEzzeddine OF, McKie PM, Dunlay SM, et al. Soluble ST2 in heart failure with preserved ejection fraction. JAHA. 2017. https:\/\/doi.org\/10.1161\/JAHA.116.004382.","journal-title":"JAHA"},{"key":"2315_CR36","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1111\/febs.12484","volume":"280","author":"E Ferraro","year":"2013","unstructured":"Ferraro E, Giammarioli AM, Caldarola S, et al. The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes. FEBS J. 2013;280:5094\u2013108. https:\/\/doi.org\/10.1111\/febs.12484.","journal-title":"FEBS J"},{"key":"2315_CR37","doi-asserted-by":"publisher","DOI":"10.2143\/AC.62.5.2023413","author":"H Sisakian","year":"2007","unstructured":"Sisakian H, Torgomyan A, Barkhudaryan A. The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy. Acta Cardiol. 2007. https:\/\/doi.org\/10.2143\/AC.62.5.2023413.","journal-title":"Acta Cardiol"},{"key":"2315_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/686304","volume":"2013","author":"O Erba\u015f","year":"2013","unstructured":"Erba\u015f O, Akseki HS, Elik\u00fc\u00e7\u00fck B, Ta\u015fk\u0131ran D. Antipsychotic-like effect of trimetazidine in a rodent model. Sci World J. 2013;2013:1\u20135.","journal-title":"Sci World J"},{"key":"2315_CR39","first-page":"6","volume":"47","author":"L Qu","year":"2018","unstructured":"Qu L, Jiang H. Clinical efficacy of trimetazidine and holistic management in the treatment of coronary heart disease. Iran J Public Health. 2018;47:6.","journal-title":"Iran J Public Health"},{"key":"2315_CR40","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2217\/fca-2017-0073","volume":"14","author":"B Bordoni","year":"2018","unstructured":"Bordoni B, Marelli F, Morabito B, Sacconi B. Depression and anxiety in patients with chronic heart failure. Future Cardiol. 2018;14:115\u20139.","journal-title":"Future Cardiol"},{"key":"2315_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4037\/ccn2014938","volume":"34","author":"DW Chapa","year":"2014","unstructured":"Chapa DW, Akintade B, Son H, et al. Pathophysiological relationships between heart failure and depression and anxiety. Crit Care Nurse. 2014;34:14\u201324.","journal-title":"Crit Care Nurse"},{"key":"2315_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40256-015-0115-6","volume":"15","author":"B DeJongh","year":"2015","unstructured":"DeJongh B, Birkeland K, Brenner M. Managing comorbidities in patients with chronic heart failure: first, do no harm. Am J Cardiovasc Drugs. 2015;15:171\u201384.","journal-title":"Am J Cardiovasc Drugs"},{"key":"2315_CR43","first-page":"145","volume":"106","author":"H Villacorta","year":"2016","unstructured":"Villacorta H, Maisel AS. Soluble ST2 testing: a promising biomarker in the management of heart failure. Arq Bras Cardiol. 2016;106:145\u201352.","journal-title":"Arq Bras Cardiol"},{"key":"2315_CR44","first-page":"123","volume":"2","author":"I Milinkovi\u0107","year":"2016","unstructured":"Milinkovi\u0107 I, Rosano G, Lopatin Y, Seferovi\u0107 PM. The role of ivabradine and trimetazidine in the new ESC HF guidelines. Card Fail Rev. 2016;2:123\u20139.","journal-title":"Card Fail Rev"},{"key":"2315_CR45","doi-asserted-by":"publisher","unstructured":"Ferrari R, Ford I, Fox K, et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. Lancet. https:\/\/www.thelancet.com\/article\/S0140-6736(20)31790-6\/fulltext. https:\/\/doi.org\/10.1016\/S0140-6736(20)31790-6.","DOI":"10.1016\/S0140-6736(20)31790-6"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02315-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02315-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02315-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T16:22:52Z","timestamp":1667146972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02315-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2315"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02315-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]},"assertion":[{"value":"2 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}